PSA Screening Rates Are Low Among Hispanic Men

Hispanic men have a low rate of guideline-appropriate prostate-specific antigen (PSA) screening, particularly if they are Black or Cuban, according to a study presented during the 25^th Annual Meeting of the Society of Urologic Oncology.

Between 2014 and 2017, Hispanic men aged 40 or older were recruited from four metropolitan areas across the United States: Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California. The prospective, population-based multicenter observational study, Hispanic Community Health Study/Study of Latinos, evaluated self-reported PSA testing of 3,484 Hispanic men.

“Hispanic men are significantly more likely to present with more advanced prostate cancer than non-Hispanic White [men],” the researchers said. “Unequal access to early prostate cancer detection may result in higher rates of prostate cancer diagnoses at an advanced stage.”

Study results showed that Black Hispanic men have the lowest odds of PSA screening in the population. Moreover, Cuban men aged 55-69 years had the lowest screening rates. Low PSA screening rates were also linked to poor primary care access. Specifically, for men aged 55-69 years with a lower BMI, low social support, or no personal doctor, remote check-up availability predicted lack of PSA screening.

Older age increased the odds of PSA screening with more than half (56%) of those 70 years or older having been screened, followed by 46% for those aged 55-69 and 20% for those aged 40-54 years. Screening rates were higher among Hispanic men who were employed, had increased family cohesion, and more social support.

“These findings underscore the within-population screening heterogeneity in this diverse community and highlight areas of targeted intervention in community health screenings,” the researchers said.

Reference

Manoharan A, Esquives BN, Penedo F, et al. Factors associated with prostate cancer screening among hispanic men: results from hispanic community health study/study of latinos (HCHS/SOL). Poster #26. Presented at the 25th Annual Meeting of the Society of Urologic Oncology; December 4-6, 2024; Dallas, Texas.